SCHEMBL295770

SCHEMBL295770

Cc1ccc2c(N3CCNCC3)nc(-c3ccccc3O)nc2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 12/20 0.61
CYP3A4 P08684 11/20 0.61
CYP2D6 P10635 8/20 0.61
TSHR P16473 5/20 0.61
CLK4 Q9HAZ1 3/20 0.61
SMAD3 P84022 1/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
MAPT P10636 4/20 0.55
CYP2C19 P33261 3/20 0.55
HSD17B10 Q99714 3/20 0.55
TDP1 Q9NUW8 1/20 0.55
ALDH1A1 P00352 6/20 0.52
KDM4E B2RXH2 3/20 0.52
L3MBTL1 Q9Y468 1/20 0.51
CHEK2 O96017 1/20 0.48
HIF1A Q16665 1/20 0.47
TP53 P04637 3/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
LMNA P02545 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1623525 0.99 CYP1A2 (0.60) CYP1A2CYP3A4CYP2D6TSHRCLK4
SCHEMBL2734047 0.90 SMAD3 (0.73) CYP1A2CYP3A4CYP2D6TSHRCLK4
SCHEMBL13769142 0.88 SMAD3 (0.71) CYP1A2CYP3A4CYP2D6TSHRCLK4
SCHEMBL5506324 0.87 SMAD3 (0.62) CYP1A2CYP3A4CYP2D6TSHRCLK4
SCHEMBL13769477 0.87 MEN1 (0.76) CYP1A2CYP3A4CYP2D6TSHRCLK4
SCHEMBL10284646 0.87 SMAD3 (0.51) CYP1A2CYP3A4CYP2D6TSHRCLK4
SCHEMBL1084946 0.86 CYP1A2 (0.61) CYP1A2CYP3A4CYP2D6TSHRCLK4
SCHEMBL1084790 0.86 SMAD3 (0.58) CYP1A2CYP3A4CYP2D6TSHRCLK4
SCHEMBL1083844 0.86 SMAD3 (0.78) CYP1A2CYP3A4CYP2D6TSHRCLK4
SCHEMBL1084224 0.85 SMAD3 (0.54) CYP1A2CYP3A4CYP2D6TSHRCLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101068794-B Quinazolines useful as modulators of ion channels VERTEX PHARMA 2012-12-19 CN disclosed
US-8283354-B2 Voltage gated sodium and calcium channel inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-09 US disclosed
US-8283354-B2 Voltage gated sodium and calcium channel inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-09 US disclosed
US-8283354-B2 Voltage gated sodium and calcium channel inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-09 US disclosed
EP-1828150-B1 PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES VERTEX PHARMA (US) 2012-03-14 EP disclosed
EP-1828150-B1 PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES VERTEX PHARMA (US) 2012-03-14 EP disclosed
EP-2366696-A1 Process for producing 4-aminoquinazolines Vertex Pharmaceuticals Incorporated (US) 2011-09-21 EP disclosed
EP-2366696-A1 Process for producing 4-aminoquinazolines Vertex Pharmaceuticals Incorporated (US) 2011-09-21 EP disclosed
US-7928107-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-19 US disclosed
US-7928107-B2 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-04-19 US disclosed
EP-1784393-B1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2009-07-01 EP disclosed
CN-101068794-A Quinazolines useful as modulators of ion channels VERTEX PHARMA (US) 2007-11-07 CN disclosed
EP-1828150-A2 PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES Vertex Pharmaceuticals Incorporated (US) 2007-09-05 EP disclosed
EP-1784393-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2007-05-16 EP disclosed
US-20060173018-A1 Quinazolines useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2006-08-03 US disclosed
US-20060166963-A1 Processes for producing 4-aminoquinazolines VERTEX PHARMACEUTICALS INCORPORATED 2006-07-27 US disclosed
WO-2006028904-A9 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2006-06-22 WO disclosed
WO-2006066044-A2 PROCESSES FOR PRODUCING 4-AMINOQUINAZOLINES VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-06-22 WO disclosed
WO-2006028904-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-03-16 WO disclosed
WO-2006010568-A2 SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, PYRIDO[3',2':4,5]FURO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, AND USE THEREOF AS INHIBITORS OF TNF-ALPHA RELEASE CURACYTE DISCOVERY GMBH (DE) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166963-A1 Processes for producing 4-aminoquinazolines CACNA1I, CACNA1G, CACNA1B CYP1A2 781/4885CYP3A4 235/4885CYP2D6 899/4885
US-20060173018-A1 Quinazolines useful as modulators of ion channels KCNQ1, KCNQ2, KCNN3 CYP1A2 2466/4885CYP3A4 2278/4885CYP2D6 2211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.